Ekf Diagnostics Holding PLC’s (EKF) “Buy” Rating Reiterated at Panmure Gordon
Ekf Diagnostics Holding PLC (LON:EKF)‘s stock had its “buy” rating reiterated by analysts at Panmure Gordon in a research note issued on Friday. They currently have a GBX 17.50 ($0.23) price target on the stock. Panmure Gordon’s price objective suggests a potential upside of 2.19% from the stock’s current price.
Other equities research analysts also recently issued research reports about the stock. N+1 Singer increased their target price on shares of Ekf Diagnostics Holding PLC from GBX 18 ($0.23) to GBX 19 ($0.25) and gave the stock a “buy” rating in a research report on Monday, September 12th. FinnCap reiterated an “under review” rating on shares of Ekf Diagnostics Holding PLC in a research report on Tuesday, August 30th.
Ekf Diagnostics Holding PLC (LON:EKF) traded up 17.094% during trading on Friday, reaching GBX 17.125. 2,089,088 shares of the company’s stock were exchanged. Ekf Diagnostics Holding PLC has a 1-year low of GBX 7.00 and a 1-year high of GBX 23.45. The company’s market capitalization is GBX 73.43 million. The company’s 50-day moving average is GBX 14.95 and its 200-day moving average is GBX 13.25.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/07/ekf-diagnostics-holding-plcs-ekf-buy-rating-reiterated-at-panmure-gordon.html
In other Ekf Diagnostics Holding PLC news, insider Mills,Christopher H. B purchased 9,000,000 shares of the business’s stock in a transaction dated Friday, July 15th. The shares were acquired at an average price of GBX 15 ($0.20) per share, for a total transaction of £1,350,000 ($1,762,172.04).
Ekf Diagnostics Holding PLC Company Profile
EKF Diagnostics Holdings Plc is focused on the In-Vitro Diagnostic device (IVD) market place. The Company is engaged in the designing, development, manufacture and selling of diagnostic instruments, reagents and certain ancillary products. This activity takes place across various geographical locations which include the United States America, Germany, Poland, Russia, United Kingdom and Ireland.
Receive News & Ratings for Ekf Diagnostics Holding PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekf Diagnostics Holding PLC and related companies with MarketBeat.com's FREE daily email newsletter.